Atranorin (Synonyms: NSC 87512, NSC 249980, NSC 685591) |
| Katalog-Nr.GC46893 |
Atranorin ist ein SekundÄrmetabolit der Flechte. Atranorin hemmt die Beweglichkeit und Tumorentstehung von Lungenkrebszellen, indem es die AP-1-, Wnt- und STAT-SignalÜbertragung beeinflusst und die RhoGTPase-AktivitÄt unterdrÜckt.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 479-20-9
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
Atranorin is a depside lichen metabolite that has been found in S. alpinum and has diverse biological activities.1,2,3,4 It is active against the bacteria B. cereus, B. subtilis, S. aureus, S. faecalis, P. vulgaris, L. monocytogenes, and A. hydrophila (MICs = 1.67, 0.38, 26.7, 13.4, 3.34, 9.83, and 1.67 mM, respectively), the fungi C. albicans and C. glabrata (MIC = 26.7 mM for both), as well as the mycobacterium M. aurum (MIC = 250 µg/ml).1,2 Atranorin is cytotoxic to A270, HL-60, and Jurkat cancer cells (IC50s = 197.9, 93.5, and 181.6 µM, respectively) but not HeLa, MCF-7, SK-BR-3, or HT-29 cancer cells (IC50s = >200 µM).3 It inhibits acetic acid-induced writhing in mice when administered orally at doses of 200 and 400 mg/kg.4 Atranorin (200 and 400 mg/kg, p.o.) also reduces paw licking and biting in the second, but not first, phase of the formalin test when administered 30 minutes prior to formalin in mice.
1.IngÓlfsdÓttir, K., Chung, G.A., SkÚlason, V.G., et al.Antimycobacterial activity of lichen metabolites in vitroEur. J. Pharm. Sci.6(2)141-144(1998) 2.Yilmaz, M., TÜrk, A.O., Tay, T., et al.The antimicrobial activity of extracts of the lichen Cladonia foliacea and its (-)-usnic acid, atranorin, and fumarprotocetraric acid constituentsZ. Naturforsch. C. J. Biosci.59(3-4)249-254(2004) 3.Ba?korovÁ, M., Ba?kor, M., Mikeš, J., et al.Variable responses of different human cancer cells to the lichen compounds parietin, atranorin, usnic acid and gyrophoric acidToxicol. In Vitro25(1)37-44(2011) 4.Melo, M.G.D., AraÚjo, A.A.S., Rocha, C.P.L., et al.Purification, physicochemical properties, thermal analysis and antinociceptive effect of atranorin extracted from Cladina kalbiiBiol. Pharm. Bull.31(10)1977-1980(2008)
| Cas No. | 479-20-9 | SDF | |
| Überlieferungen | NSC 87512, NSC 249980, NSC 685591 | ||
| Canonical SMILES | CC1=CC(OC(C2=C(O)C(C=O)=C(O)C=C2C)=O)=C(C)C(O)=C1C(OC)=O | ||
| Formula | C19H18O8 | M.Wt | 374.3 |
| Löslichkeit | Chloroform: soluble,DMSO: soluble | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.6717 mL | 13.3583 mL | 26.7165 mL |
| 5 mM | 0.5343 mL | 2.6717 mL | 5.3433 mL |
| 10 mM | 0.2672 mL | 1.3358 mL | 2.6717 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 6 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *